Toyama Chemica begins phase 3 studies in Japan with Cempra's solithromycin
Cempra announced that Toyama Chemical a subsidiary of FUJIFILM, has begun Phase 3 clinical trials with solithromycin in Japan, the world's second largest antibiotic market, for patients with community-acquired bacterial pneumonia and other respiratory infections. December 05, 2016